Vir Biotechnology Inc (VIR)
Pretax margin
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | -523,105 | -539,187 | -492,273 | -550,006 | -628,194 | -659,075 | -274,717 | -310,815 | 754,280 | 1,451,807 | 1,344,837 | 1,640,424 | 549,802 | -101,766 | -297,115 | -390,102 | -298,611 | -256,554 | -220,294 | -223,082 |
Revenue (ttm) | US$ in thousands | 73,109 | 78,618 | 72,140 | 56,343 | 46,679 | 51,681 | 427,211 | 397,246 | 1,580,474 | 2,368,441 | 2,099,722 | 2,316,395 | 1,087,060 | 277,605 | 175,080 | 67,363 | 67,245 | 67,315 | 67,364 | 1,181 |
Pretax margin | -715.51% | -685.83% | -682.39% | -976.17% | -1,345.77% | -1,275.28% | -64.30% | -78.24% | 47.72% | 61.30% | 64.05% | 70.82% | 50.58% | -36.66% | -169.70% | -579.10% | -444.06% | -381.12% | -327.02% | -18,889.25% |
December 31, 2024 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $-523,105K ÷ $73,109K
= -715.51%
The pretax margin of Vir Biotechnology Inc has exhibited significant fluctuations over the reported periods. The company experienced consistently negative pretax margins from March 2020 to June 2022, reaching its lowest point at -1,345.77% in December 2023. This indicates that during these periods, the company's operating expenses and losses exceeded its revenues.
However, the trend shifted positively from December 2022 onwards, with the pretax margin rising to 47.72% by the end of December 2022. The company continued to improve its performance, achieving a pretax margin of 70.82% in March 2023, which reversed to negative values in the subsequent quarters until December 2024.
The positive pretax margins observed in the latter part of 2022 and early 2023 signify that Vir Biotechnology Inc managed to generate profits before accounting for taxes, showcasing its ability to control costs, increase revenues, or both. Nevertheless, the subsequent negative margins suggest challenges or losses in those periods. The fluctuating pretax margins indicate the company's evolving financial performance and the need for continual monitoring and strategic adjustments to sustain profitability.
Peer comparison
Dec 31, 2024